Ketofen 1% Solution for Injection

Pajjiż: Ingilterra

Lingwa: Ingliż

Sors: VMD (Veterinary Medicines Directorate)

Ingredjent attiv:

Ketoprofen

Disponibbli minn:

Ceva Animal Health Ltd

Kodiċi ATC:

QM01AE03

INN (Isem Internazzjonali):

Ketoprofen

Għamla farmaċewtika:

Solution for injection

Tip ta 'preskrizzjoni:

POM-V - Prescription Only Medicine – Veterinarian

Grupp terapewtiku:

Cats, Dogs

Żona terapewtika:

Anti Inflammatory NSAID

L-istatus ta 'awtorizzazzjoni:

Authorized

Data ta 'l-awtorizzazzjoni:

1992-05-18

Karatteristiċi tal-prodott

Revised: October 2022
AN: 01666/2022
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Ketofen 1% solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Substance
Ketoprofen 10 mg/ml
Preservative
Benzyl alcohol 10 mg/ml
For full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs and cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the relief of pain and inflammation associated with
musculoskeletal and
other painful disorders in the dog and cat.
4.3
CONTRA-INDICATIONS
Do not use in animals suffering from cardiac, hepatic, renal disease,
where
there is a possibility of gastrointestinal ulceration or bleeding or
where there
is evidence of blood dyscrasia.
Do not administer other non-steroidal anti-inflammatory drugs
concurrently or
within 24 hours of each other.
Do not use in animals known to be hypersensitive to the active
substance.
Do not administer with diuretics or anticoagulants.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Use in any animal less than six weeks of age or in aged animals may
involve
additional risk. If such use cannot be avoided, animals may require a
reduced
dosage and careful management. Refer also to paragraphs 4.3 and 4.5.
Revised: October 2022
AN: 01666/2022
Page 2 of 4
4.5
SPECIAL PRECAUTIONS FOR USE
i. Special precautions for use in animals
Although local tolerance is not a problem, perivenous injection should
be
avoided.
Do not exceed the stated dose or duration of treatment.
Use in very young or old animals may involve additional risk. If such
a use
cannot be avoided, animals require careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as
there
is a potential risk of increased renal toxicity.
Concurrent use of potentially nephrotoxic drugs should be avoided.
Do not mix with other substances in the same syringe.
ii. Special precautions to be taken by the person administering the
medicinal
pro